login
  Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Boston Scientific launches Ingenio and Advantio family of pacemakers in Europe


Wednesday, 11 Apr 2012 10:29

Boston Scientific has announced CE mark approval and European market launch of its Ingenio and Advantio pacemakers and  Invive cardiac resynchronisation therapy pacemakers (CRT-P). Marc Burban performed one of the first implants of the Ingenio on the first week of April at the Nouvelles Cliniques Nantaises in Nantes, France. 


“The Ingenio device enables physicians to treat pacemaker patients with an advanced and comprehensive set of therapies,” said Burban. “The new RightRate pacing is easy to optimise and is designed to provide needed heart rates for patients to help them feel less fatigued during physical activity.”

“The Ingenio family of pacemakers represents a significant investment in long-term innovation for pacing technologies and defines a new era of pacing for our company,” said Joe Fitzgerald, senior vice president and president of the Boston Scientific Cardiac Rhythm Management group. “In addition, we expect to launch a series of devices with expanded capabilities, that would include remote monitoring, advanced heart failure diagnostics and compatibility with magnetic resonance imaging systems - all designed to provide innovative new features for patient health and well-being.”


The Ingenio and Advantio pacemakers feature RightRate pacing technology designed to treat chronotropic incompetence. RightRate employs Boston Scientific’s minute ventilation sensor, the only sensor clinically proven to restore chronotropic competence, and adds programming options to promote ease of use and in-clinic time savings.


The Ingenio and Advantio pacemakers are currently under review by the US Food and Drug Administration (FDA), and are currently not available for sale in the United States.




Add New Comment

Most popular


Thursday, 26 Feb 2015
Vitaria delivers autonomic regulation therapy for patients who have moderate to severe heart failure with left ventricular dysfunction (ejection fraction < 40%), and who remain symptomatic despite ... Vitaria vagal nerve stimulation system receives CE mark for treatment of chronic heart failure

Bridging during anticoagulation interruption associated with higher bleeding risk in AF patients
Friday, 30 Jan 2015
A subanalysis from the ORBIT-AF registry has found that atrial fibrillation patients who receive bridging anticoagulation therapy during anticoagulation interruption are at higher risk of bleeding ... Bridging during anticoagulation interruption associated with higher bleeding risk in AF patients

Sorin announces enrolment of first patients in the Vanguard clinical study
Thursday, 12 Feb 2015
The Vanguard (Vagal nerve stimulation safeguarding heart failure patients) clinical study evaluates Equilia, a neurostimulation system for heart failure patients. Sorin announces enrolment of first patients in the Vanguard clinical study

Features


SERVE-HF could be a wake-up call for cardiologists about central sleep apnoea
Tuesday, 24 Mar 2015
Martin Cowie (Imperial College London, London, UK) is the principal investigator of the SERVE-HF study, which is assessing the use of adaptive servo-ventilation (PaceWave, ResMed) in chronic heart ... SERVE-HF could be a wake-up call for cardiologists about central sleep apnoea

ENSURE-AF: Largest trial ever to explore novel oral anticoagulation in AF patients undergoing cardioversion
Tuesday, 10 Feb 2015
Andreas Goette explains the rationale and details of the ENSURE-AF trial, the largest prospective study evaluating the efficacy and safety of edoxaban (Daiichi Sankyo) compared with enoxaparin/... ENSURE-AF: Largest trial ever to explore novel oral anticoagulation in AF patients undergoing cardioversion

Profiles


Hung-Fat Tse
Tuesday, 03 Feb 2015
While Hung-Fat Tse’s initial research interests focused on device therapy for cardiac arrhythmias, ... Hung-Fat Tse

Massimo Santini
Friday, 10 Oct 2014
Massimo Santini performed the first fulguration of the atrioventricular node of resistant ... Massimo Santini

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions